 |
|
Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology
Eileen Laurel Yoon, Dae Won Jun
Clin Mol Hepatol. 2023;29(2):371-373. Published online 2023 Mar 14 DOI: https://doi.org/10.3350/cmh.2023.0086
|
|
Citations to this article as recorded by
 Clinical impact of five cardiometabolic risk factors in metabolic dysfunction-associated steatotic liver disease (MASLD): Insights into regional and ethnic differences
Joo Hyun Oh, Dae Won Jun
Clinical and Molecular Hepatology.2024; 30(2): 168. CrossRef Waiting for the changes after the adoption of steatotic liver disease
Eileen L. Yoon, Dae Won Jun
Clinical and Molecular Hepatology.2023; 29(4): 844. CrossRef Correspondence on Letter regarding “Waiting for the changes after the adoption of steatotic liver disease”
Eileen L. Yoon, Dae Won Jun
Clinical and Molecular Hepatology.2023; 30(1): 126. CrossRef
|